Cargando…
A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration – resistant prostate cancer patients responding to chemotherapy
PURPOSE: To investigate the toxicity and efficacy of GM-CSF in castration-resistant prostate cancer (CRPC) patients who maximized their response to systemic chemotherapy. MATERIALS AND METHODS: CRPC patients who maximized their response to either docetaxel or mitoxantrone chemotherapy were eligible...
Autores principales: | Nabhan, Chadi, Meyer, Andrew, Tolzien, Kathy, Bitran, Jacob D., Lestingi, Timothy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507059/ https://www.ncbi.nlm.nih.gov/pubmed/23210004 http://dx.doi.org/10.4103/2231-0770.83718 |
Ejemplares similares
-
A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer
por: Kruczek, K, et al.
Publicado: (2013) -
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
por: Nabhan, C, et al.
Publicado: (2012) -
Lymphangitic Pulmonary Metastases in Castrate-Resistant Prostate Adenocarcinoma
por: Meyer, Andrew, et al.
Publicado: (2012) -
Killing of Alveolar Macrophages and of Monocytes that Have Responded to Granulocyte‐Macrophage Colony‐stimulating Factor by Human Lymphokine‐activated Killer Cells
por: Sone, Saburo, et al.
Publicado: (1989) -
An Attempt to Quantitate “Value” In Medical Oncologic Therapy
por: Hancock, Christie, et al.
Publicado: (2018)